You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
HIV testing at visits to US emergency departments: 2021 update
  1. Carson Clay1,2,
  2. Brian Christopher Kuglen3,
  3. Christopher Lee Bennett2
  1. 1 NYU Grossman School of Medicine, New York, New York, USA
  2. 2 Department of Emergency Medicine, Stanford University School of Medicine, Palo Alto, California, USA
  3. 3 Department of Epidemiology, Stanford University School of Medicine, Palo Alto, California, USA
  1. Correspondence to Dr Christopher Lee Bennett, Department of Emergency Medicine, Stanford University School of Medicine, Palo Alto, California, USA; cleebennett{at}stanford.edu

Abstract

In this updated cross-sectional analysis of the National Hospital Ambulatory Medical Care Survey, we found that among the 2.5 million more weighted emergency department (ED) visits in 2021 compared with 2020, there was an insignificant increase in HIV testing per ED visit in 2021 compared with 2020 (0.81% to 0.86%). This suggests HIV testing during ED visits did not increase in line with rebounding visit volumes after the pandemic nadir.

  • HIV
  • diagnostic screening programs
  • public health

https://doi.org/10.1136/sextrans-2024-056128

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Handling editor Anna Maria Geretti

    • Contributors CC, BCK and CLB had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: CC and BCK. Acquisition, analysis or interpretation of data: all authors. Drafting of the manuscript: all authors. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: CC and BCK. Administrative, technical or material support: all authors.

    • Funding CLB reports support through the National Center for Advancing Translational Sciences (KL2TR003143) and the National Institute of Allergy and Infectious Diseases (L30AI178800).

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.